科笛-B(02487)股东将股票由花旗银行转入摩根士丹利香港证券 转仓市值1.22亿港元

Group 1 - The core point of the article highlights that on January 26, shareholders of Codi-B (02487) transferred shares from Citibank to Morgan Stanley Hong Kong Securities, with a market value of HKD 122 million, representing 7.07% of the total shares [1] - Codi-B announced positive topline results from its Phase III clinical trial in China for CU-20101 (injectable type A botulinum toxin) aimed at improving moderate to severe glabellar lines [1]